Goldman Sachs Group Inc Inozyme Pharma, Inc. Transaction History

Goldman Sachs Group Inc

$596 Billion
Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 233,561 shares of INZY stock, worth $931,908. This represents 0.0% of its overall portfolio holdings.

Number of Shares

233,561

Previous 233,561 -0.0%

Holding current value

$931,908

Previous $212,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	SELL	$0.91 - $3.07 $17,436 - $58,824	-19,161 Reduced 7.58%	233,561 $212,000
Q4 2024 Feb 11, 2025	SELL	$2.48 - $5.54 $482,595 - $1.08 Million	-194,595 Reduced 43.5%	252,722 $700,000
Q3 2024 Nov 14, 2024	BUY	$4.31 - $6.0 $368,285 - $512,694	85,449 Added 23.61%	447,317 $2.34 Million
Q2 2024 Aug 13, 2024	SELL	$4.33 - $7.31 $208,078 - $351,282	-48,055 Reduced 11.72%	361,868 $1.61 Million
Q1 2024 May 15, 2024	BUY	$4.14 - $7.66 $192,721 - $356,580	46,551 Added 12.81%	409,923 $3.14 Million
Q4 2023 Feb 13, 2024	BUY	$2.71 - $4.5 $838,701 - $1.39 Million	309,484 Added 574.31%	363,372 $1.55 Million
Q3 2023 May 14, 2024	SELL	$4.09 - $7.0 $1.27 Million - $2.17 Million	-309,484 Reduced 85.17%	53,888 $226,000
Q3 2023 Nov 14, 2023	BUY	$4.09 - $7.0 $79,750 - $136,493	19,499 Added 56.7%	53,888 $226,000
Q2 2023 May 14, 2024	BUY	$4.93 - $6.74 $110,752 - $151,414	22,465 Added 188.4%	34,389 $191,000
Q2 2023 Aug 14, 2023	BUY	$4.93 - $6.74 $169,537 - $231,781	34,389 New	34,389 $191,000
Q4 2022 May 14, 2024	SELL	$1.05 - $2.82 $610 - $1,638	-581 Reduced 4.65%	11,924 $12,000
Q4 2022 Feb 13, 2023	BUY	$1.05 - $2.82 $12,520 - $33,625	11,924 New	11,924 $12,000
Q2 2022 May 14, 2024	SELL	$3.2 - $5.96 $1.12 Million - $2.09 Million	-350,867 Reduced 96.56%	12,505 $60,000
Q2 2022 Aug 15, 2022	SELL	$3.2 - $5.96 $2,400 - $4,470	-750 Reduced 5.66%	12,505 $60,000
Q1 2022 May 16, 2022	BUY	$3.87 - $7.55 $61 - $120	16 Added 0.12%	13,255 $54,000
Q4 2021 Feb 14, 2022	SELL	$5.58 - $11.5 $18,559 - $38,249	-3,326 Reduced 20.08%	13,239 $90,000
Q3 2021 Nov 10, 2021	BUY	$11.12 - $19.4 $184,202 - $321,361	16,565 New	16,565 $192,000

Others Institutions Holding INZY

# of Institutions

Shares Held

46M

Call Options Held

13.8K

Put Options Held

View Full List

About Inozyme Pharma, Inc.

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $160M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

More about INZY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Inozyme Pharma, Inc. Transaction History